New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.11 4.60 +1.62%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

AbbVie Inc. 10-Q filed May 8, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 12:28 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 4, 2025: 13 added · 33 removed · 35 modified; 12 with only figures updated

  1. Modified

    The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of September 30March 31, 20252026 and December 31, 20242025 and the results of operations for the three and nine months ended September 30March 31, 20252026 and 20242025. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”